biostudies-literatureNelson CSNICHD NIH HHSNIAID NIH HHSHHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNIGMS NIH HHSNIH HHSDivision of Intramural Research, National Institute of Allergy and Infectious Diseases6267-6272https://www.ebi.ac.uk/biostudies/studies/S-EPMC6004431biostudies-literatureUnknown115(24)Human cytomegalovirus (HCMV) is the most common congenital infection worldwide, frequently causing hearing loss and brain damage in afflicted infants. A vaccine to prevent maternal acquisition of HCMV during pregnancy is necessary to reduce the incidence of infant disease. The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful HCMV vaccine tested to date, demonstrating ∼50% efficacy in preventing HCMV acquisition in multiple phase 2 trials. However, the mechanism of vaccine protection remains unknown. Plasma from 33 postpartum women gB/MF59 vaccinees at peak immunogenicity was tested for gB epitope specificity as well as neutralizing and nonneutralizing anti-HCMV effector functions and compared with an HCMV-seropositive cohort. gB/MF59 vaccination elicited Proceedings of the National Academy of Sciences of the United States of AmericaHCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.PMC6004431K01 OD024877R21AI136556F30 HD089577F30HD089577P30 AI064518DP2 HD075699T32 GM007171R21 AI136556DP2HD075699Huffman TXie GPass RFPermar SRJenks JAPollara JVandergrift NNelson CSCisneros de la Rosa EfalseHCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.Human cytomegalovirus (HCMV) is the most common congenital infection worldwide, frequently causing hearing loss and brain damage in afflicted infants. A vaccine to prevent maternal acquisition of HCMV during pregnancy is necessary to reduce the incidence of infant disease. The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful HCMV vaccine tested to date, demonstrating ∼50% efficacy in preventing HCMV acquisition in multiple phase 2 trials. However, the mechanism of vaccine protection remains unknown. Plasma from 33 postpartum women gB/MF59 vaccinees at peak immunogenicity was tested for gB epitope specificity as well as neutralizing and nonneutralizing anti-HCMV effector functions and compared with an HCMV-seropositive cohort. gB/MF59 vaccination elicited 2018-01-01T00:00:00Z2018 Jun2026-05-06T06:45:31.135Z2019-03-27T00:10:57ZS-EPMC60044312971286110.1073/pnas.1800177115